{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T13:30:16Z","timestamp":1783344616026,"version":"3.54.6"},"reference-count":51,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Yunnan Education Department of Science Research Fund","award":["2020J0228, 2023J0295"],"award-info":[{"award-number":["2020J0228, 2023J0295"]}]},{"name":"Kunming Medical Joint Project of Yunnan Science and Technology Department","award":["202001AY070001-271, 202301AY070001-108"],"award-info":[{"award-number":["202001AY070001-271, 202301AY070001-108"]}]},{"name":"Famous Doctors of Yunnan Province Xingdian Talents Support Program","award":["XDYC-MY-2022-0096"],"award-info":[{"award-number":["XDYC-MY-2022-0096"]}]},{"name":"Open Research Fund of Clinical Research Center for Children's Health and Diseases of Yunnan Province","award":["2022-ETYY-YJ-03"],"award-info":[{"award-number":["2022-ETYY-YJ-03"]}]},{"name":"Science and Technology project of Kunming Municipal Commission of Health and Construction","award":["No.2024-SW (lead) -7"],"award-info":[{"award-number":["No.2024-SW (lead) -7"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec>\n<jats:title>Objective<\/jats:title>\n<jats:p>Prostate cancer (PC) is the most common malignant tumour in men, and atherosclerotic cardiovascular disease (ASCVD) is the leading cause of non-cancer death in PC patients. The main purpose of this study was to investigate whether chemotherapy increases heart-specific mortality (HSM) in elderly patients with PC.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Patient information was downloaded from the Surveillance, Epidemiology, and End Results (SEER) database from 2010 to 2018. We included all elderly patients with PC. The multivariate logistic regression model was used to explore the influencing factors of patients receiving chemotherapy. Confounders were excluded using a 1:1 proportional propensity score match, and a competing risk model and cumulative incidence plot were used to analyze HSM and other cause mortality (OCM) in patients who received chemotherapy versus those who did not.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>A total of 135183 elderly prostate patients were enrolled in this study, of whom 1361 received chemotherapy. The multivariate logistic regression model showed that older patients were more likely to not receive chemotherapy, married patients were more likely to receive chemotherapy, and the higher the TNM stage and tumor histological grade, the more patients received chemotherapy. In the original cohort before unmatched, there was no significant difference in HSM between chemotherapy and non-chemotherapy patients (P = 0.27). After 1:1 matching, HSM was significantly higher in patients without chemotherapy than in patients with chemotherapy (HR 2.54; P =0.002).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Our results indicate that HSM is significantly higher in patients without chemotherapy than in those with chemotherapy. Therefore, although chemotherapy can lead to cardiotoxicity in elderly patients with PC, chemotherapy does not increase the HSM of patients and will benefit patients in the long-term survival.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0318429","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T17:24:02Z","timestamp":1744392242000},"page":"e0318429","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Chemotherapy and Heart-Specific Mortality in Elderly Men with Prostate Cancer: A Propensity Score Matching Analysis"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6421-767X","authenticated-orcid":true,"given":"Chenghao","family":"Zhanghuang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huake","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinkui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinrong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zipeng","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiacheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"issue":"1","key":"pone.0318429.ref001","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"RL Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"pone.0318429.ref002","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"RL Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"pone.0318429.ref003","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"RL Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"pone.0318429.ref004","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1136\/gutjnl-2015-310912","article-title":"Global patterns and trends in colorectal cancer incidence and mortality","volume":"66","author":"M Arnold","year":"2017","journal-title":"Gut"},{"issue":"8","key":"pone.0318429.ref005","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3390\/diagnostics10080549","article-title":"An Update on the Prognostic and Predictive Serum Biomarkers in Metastatic Prostate Cancer","volume":"10","author":"H Saxby","year":"2020","journal-title":"Diagnostics (Basel)"},{"issue":"4","key":"pone.0318429.ref006","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.eururo.2016.12.025","article-title":"Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology","volume":"72","author":"J-P Droz","year":"2017","journal-title":"Eur Urol"},{"issue":"2","key":"pone.0318429.ref007","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4103\/0971-3026.134399","article-title":"Imaging and intervention in prostate cancer: Current perspectives and future trends","volume":"24","author":"S Sharma","year":"2014","journal-title":"Indian J Radiol Imaging"},{"issue":"6_suppl","key":"pone.0318429.ref008","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1200\/JCO.2021.39.6_suppl.100","article-title":"Differential activity of PARP inhibitors in BRCA1- versus BRCA2-altered metastatic castration-resistant prostate cancer (mCRPC).","volume":"39","author":"F Taza","year":"2021","journal-title":"JCO"},{"issue":"12","key":"pone.0318429.ref009","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.2217\/fon-2016-0464","article-title":"The evolving role of chemotherapy in prostate cancer","volume":"13","author":"S Boulos","year":"2017","journal-title":"Future Oncol"},{"issue":"5","key":"pone.0318429.ref010","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1470-2045(23)00148-1","article-title":"Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol","volume":"24","author":"G Attard","year":"2023","journal-title":"Lancet Oncol"},{"issue":"5","key":"pone.0318429.ref011","doi-asserted-by":"crossref","first-page":"e541","DOI":"10.1097\/MJT.0000000000001008","article-title":"Comparative Effectiveness of All Available Treatments for Metastatic Hormone-Sensitive Prostate Cancer: A Network Meta-analysis","volume":"27","author":"M Mansourian","year":"2020","journal-title":"Am J Ther"},{"issue":"S1","key":"pone.0318429.ref012","first-page":"S110-121","article-title":"Treatment effects in prostate cancer","volume":"31","author":"AJ Evans","year":"2018","journal-title":"Mod Pathol"},{"key":"pone.0318429.ref013","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.semcancer.2021.08.011","article-title":"Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments","volume":"77","author":"C Marchetti","year":"2021","journal-title":"Semin Cancer Biol"},{"issue":"21","key":"pone.0318429.ref014","doi-asserted-by":"crossref","first-page":"e997","DOI":"10.1161\/CIR.0000000000000679","article-title":"Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors: A Scientific Statement From the American Heart Association","volume":"139","author":"SC Gilchrist","year":"2019","journal-title":"Circulation"},{"issue":"48","key":"pone.0318429.ref015","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1093\/eurheartj\/ehz766","article-title":"A population-based study of cardiovascular disease mortality risk in US cancer patients","volume":"40","author":"KM Sturgeon","year":"2019","journal-title":"Eur Heart J"},{"issue":"19","key":"pone.0318429.ref016","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1200\/JCO.2015.65.1505","article-title":"Breast Cancer Therapy-Related Cardiac Dysfunction in Adult Women Treated in Routine Clinical Practice: A Population-Based Cohort Study","volume":"34","author":"P Thavendiranathan","year":"2016","journal-title":"J Clin Oncol"},{"issue":"36","key":"pone.0318429.ref017","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: \u2002The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"JL Zamorano","year":"2016","journal-title":"Eur Heart J"},{"issue":"4","key":"pone.0318429.ref018","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.eururo.2016.12.025","article-title":"Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology","volume":"72","author":"J-P Droz","year":"2017","journal-title":"Eur Urol"},{"issue":"7 Suppl","key":"pone.0318429.ref019","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1002\/1097-0142(19941001)74:7+<2107::AID-CNCR2820741719>3.0.CO;2-1","article-title":"Clinical aspects of cancer in the elderly. Treatment decisions, treatment choices, and follow-up","volume":"74","author":"Sr McKenna RJ","year":"1994","journal-title":"Cancer"},{"issue":"1","key":"pone.0318429.ref020","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11934-015-0562-2","article-title":"Renal Cancer in the Elderly","volume":"17","author":"T Gonz\u00e1lez Le\u00f3n","year":"2016","journal-title":"Curr Urol Rep"},{"issue":"4","key":"pone.0318429.ref021","doi-asserted-by":"crossref","first-page":"35","DOI":"10.5306\/wjco.v6.i4.35","article-title":"Concurrent chemoradiation for high-risk prostate cancer","volume":"6","author":"BT Cooper","year":"2015","journal-title":"World J Clin Oncol"},{"issue":"7","key":"pone.0318429.ref022","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1200\/JCO.2012.43.6097","article-title":"Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer","volume":"31","author":"AA Forastiere","year":"2013","journal-title":"J Clin Oncol"},{"issue":"15","key":"pone.0318429.ref023","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"IF Tannock","year":"2004","journal-title":"N Engl J Med"},{"issue":"14","key":"pone.0318429.ref024","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1200\/JCO.18.02158","article-title":"Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial","volume":"37","author":"SA Rosenthal","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"pone.0318429.ref025","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S1470-2045(15)00489-1","article-title":"Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data","volume":"17","author":"CL Vale","year":"2016","journal-title":"Lancet Oncol"},{"key":"pone.0318429.ref026","doi-asserted-by":"crossref","first-page":"1533033819870815","DOI":"10.1177\/1533033819870815","article-title":"Stereotactic Ablative Radiotherapy for Prostate Cancer-The Treatment Results of 500 Patients and Analysis of Failures","volume":"18","author":"L Miszczyk","year":"2019","journal-title":"Technol Cancer Res Treat"},{"key":"pone.0318429.ref027","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.critrevonc.2019.03.014","article-title":"Consensus statements on ablative radiotherapy for oligometastatic prostate cancer: A position paper of Italian Association of Radiotherapy and Clinical Oncology (AIRO)","volume":"138","author":"RM D\u2019Angelillo","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"pone.0318429.ref028","doi-asserted-by":"crossref","first-page":"646","DOI":"10.21037\/apm-22-828","article-title":"Prostate cancer-what about oligometastatic disease and stereotactic ablative radiotherapy?-a narrative review","volume":"12","author":"C Mikropoulos","year":"2023","journal-title":"Ann Palliat Med"},{"issue":"4","key":"pone.0318429.ref029","doi-asserted-by":"crossref","first-page":"164.e19-23","DOI":"10.1016\/j.urolonc.2015.01.001","article-title":"Long-term survival of patients with locally advanced prostate cancer managed with neoadjuvant docetaxel and radical prostatectomy","volume":"33","author":"B Zhao","year":"2015","journal-title":"Urol Oncol"},{"issue":"2","key":"pone.0318429.ref030","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0090-4295(00)00914-6","article-title":"Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer","volume":"57","author":"PE Clark","year":"2001","journal-title":"Urology"},{"issue":"7","key":"pone.0318429.ref031","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S1470-2045(15)00011-X","article-title":"Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial","volume":"16","author":"K Fizazi","year":"2015","journal-title":"Lancet Oncol"},{"issue":"6","key":"pone.0318429.ref032","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.eururo.2018.01.012","article-title":"Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial","volume":"73","author":"GM Ahlgren","year":"2018","journal-title":"Eur Urol"},{"issue":"6","key":"pone.0318429.ref033","first-page":"39","article-title":"Cardiotoxicity in cancer patients treated with chemotherapy: A systematic review","volume":"16","author":"MAC Lima","year":"2022","journal-title":"Int J Health Sci (Qassim)"},{"issue":"1","key":"pone.0318429.ref034","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3349\/ymj.2019.60.1.30","article-title":"Correlation of UGT2B7 Polymorphism with Cardiotoxicity in Breast Cancer Patients Undergoing Epirubicin\/Cyclophosphamide-Docetaxel Adjuvant Chemotherapy","volume":"60","author":"H Li","year":"2019","journal-title":"Yonsei Med J"},{"issue":"3","key":"pone.0318429.ref035","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00280-019-03888-1","article-title":"Incidence of and risk factors for cardiotoxicity after fluorouracil-based chemotherapy in locally advanced or metastatic gastric cancer patients","volume":"84","author":"X Jin","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"pone.0318429.ref036","doi-asserted-by":"crossref","first-page":"188383","DOI":"10.1016\/j.bbcan.2020.188383","article-title":"Cardiovascular risks and toxicity - The Achilles heel of androgen deprivation therapy in prostate cancer patients","author":"S Muniyan","year":"2020","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"10","key":"pone.0318429.ref037","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1200\/JOP.18.00178","article-title":"Cardiovascular and Metabolic Effects of Androgen-Deprivation Therapy for Prostate Cancer","volume":"14","author":"D Gupta","year":"2018","journal-title":"J Oncol Pract"},{"issue":"19","key":"pone.0318429.ref038","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1001\/jama.2014.15554","article-title":"Progress against cardiovascular disease: putting the pieces together","volume":"312","author":"P Greenland","year":"2014","journal-title":"JAMA"},{"issue":"42","key":"pone.0318429.ref039","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1093\/eurheartj\/ehw334","article-title":"Cardiovascular disease in Europe: epidemiological update 2016","volume":"37","author":"N Townsend","year":"2016","journal-title":"Eur Heart J"},{"issue":"1","key":"pone.0318429.ref040","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.eururo.2012.08.070","article-title":"Neoadjuvant hormonal therapy use and the risk of death in men with prostate cancer treated with brachytherapy who have no or at least a single risk factor for coronary artery disease","volume":"65","author":"A Nanda","year":"2014","journal-title":"Eur Urol"},{"issue":"12","key":"pone.0318429.ref041","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1023\/A:1008315312795","article-title":"Doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients: the M.D. Anderson experience, with long-term follow-up","volume":"11","author":"NK Ibrahim","year":"2000","journal-title":"Ann Oncol"},{"issue":"23","key":"pone.0318429.ref042","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1182\/blood.V126.23.3914.3914","article-title":"Risk Factors for Early Death after Immunochemotherapy in Older Patients with Diffuse Large B-Cell Lymphoma (DLBCL)","volume":"126","author":"K Mantripragada","year":"2015","journal-title":"Blood"},{"issue":"1","key":"pone.0318429.ref043","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/CAD.0b013e32835a56bc","article-title":"Peg-filgrastim and cabazitaxel in prostate cancer patients","volume":"24","author":"G Di Lorenzo","year":"2013","journal-title":"Anticancer Drugs"},{"issue":"6","key":"pone.0318429.ref044","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.eururo.2013.07.022","article-title":"Taxane mechanisms of action: potential implications for treatment sequencing in metastatic castration-resistant prostate cancer","volume":"65","author":"JM Fitzpatrick","year":"2014","journal-title":"Eur Urol"},{"issue":"18","key":"pone.0318429.ref045","doi-asserted-by":"crossref","first-page":"6019","DOI":"10.1158\/0008-5472.CAN-11-1417","article-title":"Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer","volume":"71","author":"MS Darshan","year":"2011","journal-title":"Cancer Res"},{"issue":"2","key":"pone.0318429.ref046","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.eururo.2011.04.038","article-title":"New therapies for castration-resistant prostate cancer: efficacy and safety","volume":"60","author":"H Beltran","year":"2011","journal-title":"Eur Urol"},{"issue":"6","key":"pone.0318429.ref047","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1038\/s41416-024-02810-8","article-title":"CDK9 inhibition inhibits multiple oncogenic transcriptional and epigenetic pathways in prostate cancer","volume":"131","author":"R Rahman","year":"2024","journal-title":"Br J Cancer"},{"issue":"Suppl 1","key":"pone.0318429.ref048","first-page":"57","article-title":"Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer","volume":"10","author":"V Lohiya","year":"2016","journal-title":"Clin Med Insights Oncol"},{"issue":"6","key":"pone.0318429.ref049","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.eururo.2021.01.017","article-title":"CD38 in Advanced Prostate Cancers","volume":"79","author":"C Guo","year":"2021","journal-title":"Eur Urol"},{"key":"pone.0318429.ref050","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.radonc.2020.09.009","article-title":"Lead-time bias does not falsify the efficacy of early salvage radiotherapy for recurrent prostate cancer","volume":"154","author":"D Bartkowiak","year":"2021","journal-title":"Radiother Oncol"},{"issue":"4","key":"pone.0318429.ref051","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.urolonc.2023.11.013","article-title":"Estimates of the lead time in screening for bladder cancer","volume":"42","author":"J Benbassat","year":"2024","journal-title":"Urol Oncol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0318429","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T17:24:21Z","timestamp":1744392261000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0318429"}},"subtitle":[],"editor":[{"given":"Xing","family":"Xiong,","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":51,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0318429","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]}}}